Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency
Author:
Funder
National Natural Science Foundation of China
Publisher
Frontiers Media SA
Subject
Immunology,Immunology and Allergy
Reference12 articles.
1. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer;Garon;N Engl J Med,2015
2. Role of the Tumor Microenvironment in PD-L1/PD-1-mediated Tumor Immune Escape;Jiang;Mol Cancer,2019
3. B Cells Inhibit Induction of T Cell-Dependent Tumor Immunity;Qin;Nat Med,1998
4. B Cell Depletion or Absence Does Not Impede Anti-Tumor Activity of PD-1 Inhibitors;Damsky;J ImmunoTher Cancer,2019
5. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti–PD-1/PD-L1;Champiat;Clin Cancer Res,2017
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Peripheral B-cell levels predict efficacy and overall survival in advanced melanoma patients under PD-1 immunotherapy;Immunotherapy;2024-03
2. Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report;Molecular and Clinical Oncology;2024-02-23
3. Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms;BMC Endocrine Disorders;2022-11-22
4. Role of fibrosarcoma-induced CD11b+ myeloid cells and tumor necrosis factor-α in B cell responses;Oncogene;2022-01-15
5. Antineoplastics;Reactions Weekly;2021-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3